AC Immune (ACIU) Research & Development (2015 - 2026)
AC Immune (ACIU) reported Research & Development of -$15.0 million for Q1 2026, up 15.28% year-over-year from -$13.0 million in Q1 2025, and down 12.84% on a QoQ basis from -$13.3 million in Q4 2025.
AC Immune (ACIU) has 12 years of Research & Development data on file, last reported at -$15.0 million in Q1 2026.
- Quarterly Research & Development rose 15.28% year-over-year to -$15.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$65.0 million (up 9.01% YoY) and the FY2025 annual result came in at -$68.1 million, up 4.7% from the prior year.
- Research & Development fell to -$15.0 million in Q1 2026 per ACIU's latest filing, from -$13.3 million in the prior quarter.
- Across five years, Research & Development topped out at -$13.3 million in Q4 2025 and bottomed at -$20.3 million in Q2 2025.
- The 5-year median for Research & Development is -$16.3 million (2025), against an average of -$16.3 million.
- The widest annual swing landed in 2022, when Research & Development gained 28.01%; it then fell 24.54% in 2024.
- Tracing ACIU's Research & Development over 5 years: stood at -$15.7 million in 2022, then dropped by 5.08% to -$16.5 million in 2023, then slipped by 9.15% to -$18.0 million in 2024, then grew by 26.24% to -$13.3 million in 2025, then decreased by 12.84% to -$15.0 million in 2026.
- Per Business Quant, the three latest ACIU Research & Development figures stand at -$15.0 million (Q1 2026), -$13.3 million (Q4 2025), and -$16.3 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 364.87 Mn |
| 10 | AC Immune | 325.88 Mn | 211.53 Mn | - | -15.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -15.00 Mn |
| Dec 31, 2025 | -13.29 Mn |
| Sep 30, 2025 | -16.34 Mn |
| Jun 30, 2025 | -20.32 Mn |
| Mar 31, 2025 | -17.70 Mn |
| Dec 31, 2024 | -18.02 Mn |
| Sep 30, 2024 | -16.72 Mn |
| Jun 30, 2024 | -18.95 Mn |
| Mar 31, 2024 | -17.37 Mn |
| Dec 31, 2023 | -16.51 Mn |
| Sep 30, 2023 | -14.05 Mn |
| Jun 30, 2023 | -15.22 Mn |
| Mar 31, 2023 | -15.00 Mn |
| Dec 31, 2022 | -15.71 Mn |
| Sep 30, 2022 | -14.90 Mn |
| Jun 30, 2022 | -16.29 Mn |
| Mar 31, 2022 | -16.38 Mn |
| Dec 31, 2021 | -21.82 Mn |
| Sep 30, 2021 | -16.47 Mn |
| Jun 30, 2021 | -15.04 Mn |
| Mar 31, 2021 | -14.74 Mn |
| Dec 31, 2020 | -17.64 Mn |
| Sep 30, 2020 | -16.86 Mn |
| Jun 30, 2020 | -13.29 Mn |
| Mar 31, 2020 | -15.72 Mn |
| Dec 31, 2019 | -14.81 Mn |
| Sep 30, 2019 | -11.65 Mn |
| Jun 30, 2019 | -12.67 Mn |
| Mar 31, 2019 | -11.64 Mn |
| Dec 31, 2018 | -12.19 Mn |
| Sep 30, 2018 | -11.74 Mn |
| Jun 30, 2018 | -10.70 Mn |
| Mar 31, 2018 | -10.62 Mn |
| Mar 31, 2017 | -7.42 Mn |
| Dec 31, 2016 | 37.20 Mn |
| Sep 30, 2016 | -7.89 Mn |
| Mar 31, 2016 | -5.41 Mn |
| Dec 31, 2015 | 10.75 Mn |
| Sep 30, 2015 | -4.31 Mn |